



Limited Liability Company ("naamloze vennootschap")
Registered Office: Generaal de Wittelaan 11B, 2800 Mechelen, Belgium
Company Number VAT BE 0505.640.808 RLP Antwerp, division Mechelen

VOTE BY MAIL FORM

ANNUAL SHAREHOLDERS' MEETING

to be held on Friday 10 May 2019 at 2:00 p.m. CEST

*This is an unofficial English translation, for information purposes only.
Please only sign and return the original Dutch version.*

This form should be used by holders of shares of Biocartis Group NV (the "Company") who want to vote by mail.

The vote by mail form must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, or an electronic signature that complies with the conditions set out in Article 1322 of the Belgian Civil Code.

The signed and completed form must reach the Company at the latest on the sixth calendar day prior to the annual shareholders' meeting, i.e. on or before Saturday 4 May 2019 at the latest. Forms sent to the Company must be sent by mail to:

Biocartis Group NV
Attention: Tim Vandorpe
Corporate Counsel
Generaal de Wittelaan 11B
2800 Mechelen
Belgium

or by e-mail to:

legal@biocartis.com

Holders of shares of the Company who wish to vote by mail must also register for the annual shareholders' meeting, as described in the notice convening the annual shareholders' meeting. Holders of dematerialized shares must attach to the present form a certificate issued by the applicable settlement institution for the shares concerned, or by a certified account holder, confirming the number of shares that have been registered in their name on the registration date (i.e. Friday 26 April 2019, at midnight (12:00 a.m., Central European Summer Time)) with which they want to participate to the annual shareholders' meeting.

In case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar day prior to the annual shareholders' meeting, i.e. on or before Thursday 25 April 2019 at the latest. At that time, the Company will also make available amended forms for votes by mail. Votes by mail that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the votes by mail apply, subject, however, to applicable law and the further clarifications set out in this form. In accordance with the Belgian Companies Code, a

vote via vote by mail for an agenda item in relation to which a new proposed resolution has been submitted by one or more shareholders holding at least 3% of the share capital, is invalid.

The undersigned (the "Undersigned")

First Name:

Family Name:

Address:

or

Corporate name:

Corporate form:

Registered office:

Represented by (first name, family name and capacity):

.....

.....

.....

owner of the following number of shares issued by Biocartis Group NV, with its registered office at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium:

Number of shares
Form of the above mentioned shares <i>(please tick the appropriate box):</i>	
<input type="checkbox"/> Registered	
<input type="checkbox"/> Dematerialized	

Hereby irrevocably votes, as indicated hereafter in the appropriate boxes, on the items of the following agenda:

ANNUAL SHAREHOLDERS' MEETING

Agenda and proposed resolutions: The agenda and proposed resolutions of the annual shareholders' meeting of the Company, which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Reports on the statutory financial statements and on the consolidated financial statements

Submission of, and discussion on: (a) the combined annual report of the Board of Directors on the statutory financial statements and the consolidated financial statements for the financial year ended on 31 December 2018, (b) the report of the statutory auditor on the statutory financial statements for the financial year ended on 31 December 2018, and (c) the report of the statutory auditor on the consolidated financial statements for the financial year ended on 31 December 2018.

2. Approval of the statutory financial statements

Approval of the statutory financial statements for the financial year ended on 31 December 2018, and of the proposed allocation of the result.

Proposed resolution: The annual shareholders' meeting approves the statutory financial statements for the financial year ended on 31 December 2018, as well as the allocation of the result as proposed by the Board of Directors.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

3. Consolidated financial statements

Submission of the consolidated financial statements for the financial year ended on 31 December 2018.

4. Discharge from liability of the directors

Proposed resolution: The annual shareholders' meeting grants discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2018, for the performance of their mandate during that financial year.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

5. Discharge from liability of the statutory auditor

Proposed resolution: The annual shareholders' meeting grants discharge from liability to the statutory auditor for the performance of its mandate during the financial year ended on 31 December 2018.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

6. Remuneration report

Submission of, discussion on and approval of the remuneration report prepared by the Remuneration and Nomination Committee, and included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

Proposed resolution: The annual shareholders' meeting approves the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

7. Re-appointment of Roald Borré as director

Taking into account the advice of the Remuneration and Nomination Committee, the Board of Directors recommends that Roald Borré be re-appointed as director of the Company for a term of one year. For further information regarding this proposed director, reference is made to the corporate governance statement included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

Proposed resolution: Roald Borré is re-appointed as director of the Company for a term of one year, up to and including the closing of the annual shareholders' meeting to be held in 2020 which will have decided upon the financial statements for the financial year ended on 31 December 2019. The mandate of the director shall be remunerated as set out in relation to non-executive directors in the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2018, and pursuant to the principles approved by the annual shareholders' meeting held on 11 May 2018.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

8. Confirmation of the appointment of Scientia II, LLC, represented by Harry Glorikian, as independent director

On 11 May 2018, Harry Glorikian was appointed as independent director of the Company. On 21 June 2018, Harry Glorikian resigned as director, but at his request Scientia II, LLC, a company controlled by Harry Glorikian, was appointed by the Board of Directors of the Company to replace Harry Glorikian as independent director of the Company. In view hereof, and taking into account the advice of the Remuneration and Nomination Committee, the Board of Directors recommends that the appointment of Scientia II, LLC, represented by Harry Glorikian as permanent representative, be confirmed. It appears from information available to the Company and from information provided by Harry Glorikian that each of Scientia II, LLC and Harry Glorikian satisfy the applicable requirements with respect to independence. For further information as to Harry Glorikian, reference is made to the corporate governance statement included in the annual report of the Board of Directors for the financial year ended on 31 December 2018.

Proposed resolution: The annual shareholders' meeting takes note of the resignation of Harry Glorikian as director of the Company on 21 June 2018 and confirms the appointment of Scientia II, LLC, a limited liability company, represented by Harry Glorikian as permanent representative, as independent director of the Company, within the meaning of Article 526ter of the Belgian Companies Code and provision 2.3 of the Belgian Code on Corporate Governance, for the remainder of the term of Harry Glorikian, being a term up to and including the closing of the annual shareholders' meeting to be held in 2020 which will have decided upon the financial

statements for the financial year ended on 31 December 2019. The mandate of the director shall be remunerated as set out in relation to independent directors in the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2018, and pursuant to the principles approved by the annual shareholders' meeting held on 11 May 2018.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

9. Application of Article 556 of the Belgian Companies Code

Proposed resolution: In accordance with Article 556 of the Belgian Companies Code, the annual shareholders' meeting resolves to approve, and to the extent required, ratify all terms and conditions of the warrant plan named "Warrant Plan 2018" that was created by the Board of Directors on 10 September 2018 pursuant to the authorized capital which grant rights to third parties which could affect the assets of the Company, or could impose an obligation on the Company, where the exercise of those rights is dependent on a public takeover bid on the shares of the Company or a change of control in respect of the Company, including without limitation, the accelerated vesting mechanism in the event a public takeover bid is made on the Company's securities. The annual shareholders' meeting further grants a special power of attorney to each director of the Company, as well as to Mr. Ewoud Welten and Mr. Tim Vandorpe, each acting individually and with the power of substitution, to perform the formalities required by Article 556 of the Belgian Companies Code with respect to this resolution.

Voting instruction:

<input type="checkbox"/> I AGREE	<input type="checkbox"/> I DO NOT AGREE	<input type="checkbox"/> ABSTENTION
----------------------------------	---	-------------------------------------

* * *

The aforementioned votes apply to the annual shareholders' meeting that will be held on Friday 10 May 2019. In case the aforementioned annual shareholders' meeting would be postponed or suspended, the aforementioned votes will also apply to the general meeting that would be held having the same agenda, as relevant:

Yes

No

Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the Undersigned shall be deemed to have selected "Yes". Please note that in order to apply for such subsequent meeting, holders of shares must again register for such meeting.

In case of amendments during the meeting to a proposed resolution or in case of a new proposed resolution during the meeting:¹

the Undersigned votes for the amended or new resolution

the Undersigned votes against the amended or new resolution

the Undersigned abstains from the vote on the amended or new resolution

- the following person is appointed as special proxy holder, with power of substitution, to vote in the name of the Undersigned on the amended or new resolution: Mr./Mrs.
.....²

¹ Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended proposed resolution or new proposed resolution.

² In case the Chairman of the Board of Directors of the Company is appointed as special proxy holder, the Chairman (or, as the case may be, another Director, employee or agent of the Company appointed as substitute of the Chairman pursuant to a sub delegation if the Chairman is hindered to participate in the general shareholders' meeting) will in such event vote on the amended proposed resolutions or new proposed resolutions in the manner as will be supported or recommended by the Board of Directors. Please note that the Chairman of the Board of Directors of the Company (or, as the case may be, the substitute of the Chairman) is a director, employee or agent of Biocartis Group NV and therefore has a potential conflict of interest as provided for in Article 547bis, §4 of the Belgian Companies Code.

This voting letter shall also serve as notification within the meaning of Article 536, §2, par. 3 of the Belgian Companies Code with respect to the annual shareholders' meeting of the Company to be held on Friday 10 May 2019.

Done at, on2019

Signature.....